VEGF-A enhances the cytotoxic function of CD4+ cytotoxic T cells via the VEGF-receptor 1/VEGF-receptor 2/AKT/mTOR pathway

被引:9
|
作者
Chen, Ziyi [1 ]
Zhang, Meng [1 ]
Liu, Yufeng [2 ,3 ,4 ]
Chen, Zhe [5 ]
Wang, Ling [1 ]
Wang, Wenjuan [6 ]
Wang, Jincheng [6 ]
He, Mingqian [1 ]
Shi, Bingyin [1 ]
Wang, Yue [1 ,2 ,3 ]
机构
[1] Xi An Jiao Tong Univ, Dept Endocrinol, Affiliated Hosp 1, Xian, Peoples R China
[2] Xi An Jiao Tong Univ, Sch Elect & Informat Engn, MOE Key Lab Intelligent Networks & Networks Secur, Xian, Peoples R China
[3] Xi An Jiao Tong Univ, Genome Inst, Affiliated Hosp 1, Xian, Peoples R China
[4] Xi An Jiao Tong Univ, BioBank, Affiliated Hosp 1, Xian, Peoples R China
[5] Xi An Jiao Tong Univ, Hong Hui Hosp, Dept Spine Surg, Xian, Peoples R China
[6] Xi An Jiao Tong Univ, Dept Hematol, Affiliated Hosp 1, Xian, Peoples R China
基金
中国国家自然科学基金;
关键词
CD4(+) cytotoxic T cells; CD4; CTLs; VEGF-A; VEGF-R1; VEGF-R2; mTOR; Graves orbitopathy; ENDOTHELIAL GROWTH-FACTOR; INFLAMMATION; ANGIOGENESIS; POLARIZATION; LYMPHOCYTES; ACTIVATION; EXPRESSION; AKT;
D O I
10.1186/s12967-023-03926-w
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BackgroundCD4(+) cytotoxic T cells (CD4 CTLs) are CD4(+) T cells with major histocompatibility complex-II-restricted cytotoxic function. Under pathologic conditions, CD4 CTLs hasten the development of autoimmune disease or viral infection by enhancing cytotoxicity. However, the regulators of the cytotoxicity of CD4 CTLs are not fully understood.MethodsTo explore the potential regulators of the cytotoxicity of CD4 CTLs, bulk RNA and single-cell RNA sequencing (scRNA-seq), enzyme-linked immunosorbent assay, flow cytometry, quantitative PCR, and in-vitro stimulation and inhibition assays were performed.ResultsIn this study, we found that VEGF-A promoted the cytotoxicity of CD4 CTLs through scRNA-seq and flow cytometry. Regarding the specific VEGF receptor (R) involved, VEGF-R1/R2 signaling was activated in CD4 CTLs with increased cytotoxicity, and the VEGF-A effects were inhibited when anti-VEGF-R1/R2 neutralizing antibodies were applied. Mechanistically, VEGF-A treatment activated the AKT/mTOR pathway in CD4 CTLs, and the increases of cytotoxic molecules induced by VEGF-A were significantly reduced when the AKT/mTOR pathway was inhibited.ConclusionIn conclusion, VEGF-A enhances the cytotoxicity of CD4 CTLs through the VEGF-R1/VEGF-R2/AKT/mTOR pathway, providing insights for the development of novel treatments for disorders associated with CD4 CTLs.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] VEGF-A enhances the cytotoxic function of CD4+ cytotoxic T cells via the VEGF-receptor 1/VEGF-receptor 2/AKT/mTOR pathway
    Ziyi Chen
    Meng Zhang
    Yufeng Liu
    Zhe Chen
    Ling Wang
    Wenjuan Wang
    Jincheng Wang
    Mingqian He
    Bingyin Shi
    Yue Wang
    Journal of Translational Medicine, 21
  • [2] An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
    Palazon, Asis
    Tyrakis, Petros A.
    Macias, David
    Velica, Pedro
    Rundqvist, Helene
    Fitzpatrick, Susan
    Vojnovic, Nikola
    Phan, Anthony T.
    Loman, Niklas
    Hedenfalk, Ingrid
    Hatschek, Thomas
    Lovrot, John
    Foukakis, Theodoros
    Goldrath, Ananda W.
    Bergh, Jonas
    Johnson, Randall S.
    CANCER CELL, 2017, 32 (05) : 669 - +
  • [3] Increased spontaneous production of VEGF by CD4+ T cells in type 1 diabetes
    Marek, Natalia
    Mysliwiec, Malgorzata
    Raczynska, Krystyna
    Zorena, Katarzyna
    Mysliwska, Jolanta
    Trzonkowski, Piotr
    CLINICAL IMMUNOLOGY, 2010, 137 (02) : 261 - 270
  • [4] Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and-2 mRNA expression profiles between clear cell and papillary renal cell carcinoma
    Ljungberg, Borje J.
    Jacobsen, Jan
    Rudolfsson, Stina Haggstrom
    Lindh, Gudrun
    Grankvist, Kjell
    Rasmuson, Torgny
    BJU INTERNATIONAL, 2006, 98 (03) : 661 - 667
  • [5] VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
    Gavalas, N. G.
    Tsiatas, M.
    Tsitsilonis, O.
    Politi, E.
    Ioannou, K.
    Ziogas, A. C.
    Rodolakis, A.
    Vlahos, G.
    Thomakos, N.
    Haidopoulos, D.
    Terpos, E.
    Antsaklis, A.
    Dimopoulos, M. A.
    Bamias, A.
    BRITISH JOURNAL OF CANCER, 2012, 107 (11) : 1869 - 1875
  • [6] Kochia scoparia seed extract suppresses VEGF-induced angiogenesis via modulating VEGF receptor 2 and PI3K/AKT/mTOR pathways
    Cho, Hyun-Dong
    Kim, Jeong-Ho
    Park, Jun-Kyu
    Hong, Seong-Min
    Kim, Du-Hyun
    Seo, Kwon-Il
    PHARMACEUTICAL BIOLOGY, 2019, 57 (01) : 684 - 693
  • [7] VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2
    Ziogas, Apostolos C.
    Gavalas, Nikos G.
    Tsiatas, Marinos
    Tsitsilonis, Ourania
    Politi, Ekaterini
    Terpos, Evangelos
    Rodolakis, Alexandros
    Vlahos, George
    Thomakos, Nikolaos
    Haidopoulos, Dimitrios
    Antsaklis, Aristidis
    Dimopoulos, Meletios A.
    Bamias, Aristotle
    INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (04) : 857 - 864
  • [8] t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt
    Imai, Norikazu
    Shikami, Masato
    Miwa, Hiroshi
    Suganuma, Kazuto
    Hiramatsu, Akihito
    Watarai, Masaya
    Satoh, Atsushi
    Itoh, Masato
    Imamura, Akira
    Mihara, Hidetsugu
    Nitta, Masakazu
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (05) : 673 - 682
  • [9] VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
    N G Gavalas
    M Tsiatas
    O Tsitsilonis
    E Politi
    K Ioannou
    A C Ziogas
    A Rodolakis
    G Vlahos
    N Thomakos
    D Haidopoulos
    E Terpos
    A Antsaklis
    M A Dimopoulos
    A Bamias
    British Journal of Cancer, 2012, 107 : 1869 - 1875
  • [10] VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding
    Lanitis, Evripidis
    Kosti, Paris
    Ronet, Catherine
    Cribioli, Elisabetta
    Rota, Giorgia
    Spill, Aodrenn
    Reichenbach, Patrick
    Zoete, Vincent
    Laniti, Denarda Dangaj
    Coukos, George
    Irving, Melita
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)